Welcome to our dedicated page for Arev Life Sciences Global news (Ticker: AREVF), a resource for investors and traders seeking the latest updates and insights on Arev Life Sciences Global stock.
This page contains historical news coverage for AREV Life Sciences Global Corp (AREVF), which operated as a pharmaceutical preparation manufacturing company. The company focused on developing products within the life sciences sector, including pharmaceutical preparations and nutraceutical ventures. AREV has ceased active operations and no longer generates news coverage.
Historical news articles for AREV Life Sciences document the company's business developments, operational updates, and management appointments during its active period. This archive provides context on the company's stated business objectives, laboratory operations, and attempts to establish a position within the pharmaceutical manufacturing space.
The pharmaceutical preparation manufacturing industry generates news related to product development milestones, regulatory approvals, partnership announcements, and operational updates. For micro-cap pharmaceutical ventures like AREV, news coverage typically focused on business developments, facility completions, and compliance activities rather than major product launches or clinical trial results.
This historical archive documents AREV Life Sciences' journey as a small-cap pharmaceutical venture, providing insight into the challenges and developments that characterized the company's operational period. Investors researching defunct pharmaceutical stocks can use this archive to understand the company's history and the circumstances surrounding its cessation of operations.
AREV Life Sciences Global Corp. has appointed Kevin Phelps, CPA, as the Chief Operating Officer to facilitate its growth and expansion. Phelps, with over 40 years of experience in biotechnology and business, served in various executive roles, including as CEO and CFO. The company also announced a retention warrant offering for its senior management, including a pricing structure and exercise provisions. Insiders' participation in this offering qualifies as a 'related party transaction' but is exempt from formal valuation. AREV focuses on delivering therapeutic solutions through innovative drug design and collaborations.
AREV Life Sciences Global Corp. (CSE: AREV, OTC: AREVF) has announced its initial research engagement with TransBIOTech, a supported preclinical research organization. This collaboration aims to explore the therapeutic potential of cannabinoids and address public health challenges. Leveraging proprietary extraction technologies, AREV plans to conduct studies on immune modulation and phytomedicinal therapeutics. Initial studies will focus on understanding the pharmacological properties of compounds, with a goal of satisfying regulatory requirements for human studies and eventual commercialization.
AREV Life Sciences Global Corp. has completed its fungi inoculation lab in Coquitlam, focusing on Lion's Mane mushrooms. The company achieves a 10% extraction yield, regarded as exceptional by experts. This milestone enhances revenue streams and positions AREV for potential applications in health products and drug development. Lion's Mane's compounds may offer various health benefits, including brain protection and anti-inflammatory properties. However, human studies are still required to confirm efficacy.
AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) announced new acquisitions and product developments on Feb. 17, 2022. Key appointments include Douglas Sorocco to the scientific advisory committee and IP council, enhancing corporate capacity. The company is focused on its ready-to-use therapeutic food, SUSTAINN, amid a global famine crisis. Additionally, AREV extended its partnership with Strategic Health Resources LLC to gain formulary inclusion for SUSTAINN. The company also issued 100,000 stock options to key personnel at a price of $0.29 each.
FAQ
What is the current stock price of Arev Life Sciences Global (AREVF)?
What is the market cap of Arev Life Sciences Global (AREVF)?
